Recruiting Type 2 Diabetes Studies in Columbus
About Type 2 Diabetes Clinical Trials in Columbus
Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.
There are currently 1 type 2 diabetes clinical trials recruiting participants in Columbus, OHIO. These studies are seeking a combined 230 participants. Research is being sponsored by Energenesis Biomedical Co., Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 2 Diabetes Clinical Trials in Columbus — FAQ
Are there type 2 diabetes clinical trials in Columbus?
Yes, there are 1 type 2 diabetes clinical trials currently recruiting in Columbus, OHIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Columbus?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you about next steps.
Are clinical trials in Columbus free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbus studies also compensate for your time and travel.
What type 2 diabetes treatments are being tested?
The 1 active trials in Columbus are testing new therapies including novel drugs, biologics, and treatment approaches for type 2 diabetes.
Data updated March 2, 2026 from ClinicalTrials.gov